Core Viewpoint - Novo Nordisk strongly urges the U.S. Department of Commerce not to impose tariffs on pharmaceuticals, warning that such measures could disrupt access to critical medications [2][4]. Group 1: Tariff Concerns - The company opposes blanket tariffs on all drug imports and suggests that the Department of Commerce focus on investigating the import of semaglutide from unknown sources, particularly unauthorized imports from China [2][4]. - Novo Nordisk highlights that unauthorized semaglutide imports from China hinder its investments in the U.S. and pose potential national security threats due to inadequate FDA oversight [2][4]. Group 2: Regulatory Issues - Among the 19 Chinese companies exporting semaglutide raw materials to the U.S., 12 are deemed non-compliant with Good Manufacturing Practices (GMP) [4]. - The company calls for the Department of Commerce to prioritize combating illegal imports and to collaborate with European allies to establish a more robust pharmaceutical supply chain [4]. Group 3: Industry Response - Novo Nordisk emphasizes that maintaining the security and integrity of the supply chain is crucial for ensuring U.S. patients have continuous access to high-quality medications [5]. - Other major pharmaceutical companies, such as Amgen, have also expressed opposition to tariffs, advocating for favorable tax policies to promote domestic drug production instead [5]. Group 4: Price Control Concerns - Many voices in the pharmaceutical industry are focused on Trump's proposed "Most Favored Nation Drug Pricing" executive order, which aims to align U.S. drug prices with those in other developed countries [6]. - Takeda's U.S. president has indicated that this executive order could have a potential impact of up to $1 trillion on the industry over the next decade, while AbbVie warns that such price control measures could harm the U.S. healthcare sector and stifle future innovation [6].